About 19 results found for searched term "PARP-1-IN-3" (0.147 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41572 | PARP-1-IN-3 | PARP |
| PARP-1-IN-3, a benzamide derivative, is a potent PARP-1 inhibitor with IC50 values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. | ||
| M41577 | PARP-1-IN-13 | PARP |
| PARP-1-IN-13 is a PARP-1 inhibitor (IC50: 26 nM). | ||
| M2215 | Niraparib (MK-4827) | PARP |
| MK-4827 | ||
| MK-4827 (Niraparib) is a selective PARP1/2 inhibitor with an IC50 value of 3.8 nM/2.1 nM that increases the formation of PARP-DNA complexes through inhibition of PARPase activity, leading to DNA damage, apoptosis, PARP-1-dependent cell death (parthanatos) and cell death. Strong effector activity when acting on cancer cells harboring mutant BRCA-1 and BRCA-2. It is more than 330-fold more selective than PARP3, V-PARP and Tank1. | ||
| M2587 | JW55 | PARP |
| JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively. | ||
| M5270 | NMS-P118 | PARP |
| NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively). | ||
| M8926 | Niraparib (MK-4827) tosylate | PARP |
| MK-4827 tosylate | ||
| Niraparib (MK-4827) tosylate is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively. | ||
| M10298 | AZD5305 | PARP |
| Saruparib; AZD-5305 | ||
| Saruparib (AZD5305) is a potent and oral active, second-generation PARP (highly selective PARP1) inhibitor with IC50 values of 3 nM and 1400 nM for PARP1 and PARP2, respectively. | ||
| M13391 | RBN012759 | PARP |
| RBN012759 is a potent, selective and orally active PARP14 inhibitor with IC50 values of <3 nM and 5 nM against the human and mouse catalytic domains, respectively. AIDS in the anti-tumor immune response. | ||
| M13711 | Niraparib hydrochloride | PARP |
| MK-4827 hydrochloride | ||
| Niraparib hydrochloride (MK-4827 hydrochloride) is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. | ||
| M21446 | AZD-9574 | PPAR |
| AZD-9574 is a best-in-class, potent, blood-brain barrier permeable PARP1 inhibitor that exhibits >8000-fold selectivity for PARP1 over PARP2/3/5a/6.AZD-9574 selectively inhibits PARP1 at the SSB site.AZD-9574 is an anticancer AZD-9574 is an anticancer compound that can be used in HRD+ breast cancer and advanced solid malignant tumor studies. | ||
| M22487 | RBN-3143 | PARP |
| RBN3143 | ||
| RBN-3143 is a potent and NAD+-competitive catalytic PARP14 inhibitor with an IC50 value of 4 nM. RBN-3143 inhibits PARP14-mediated ADP-ribosylation and stabilizes PARP14 in cell lines. | ||
| M28680 | Niraparib tosylate hydrate | PARP |
| MK-4827 tosylate hydrate | ||
| Niraparib (MK-4827) tosylate hydrate is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor with IC50s of 3.8 and 2.1 nM, respectively. Niraparib tosylate hydrate leads to inhibition of repair of DNA damage, activates apoptosis and shows anti-tumor activity. | ||
| M29181 | PARP14 inhibitor H10 | PARP |
| PARP14 inhibitor H10, compound H 10, is a selective inhibitor against PARP14 (IC50=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis. | ||
| M29548 | PROTAC PARP1 degrader | PROTAC |
| PROTAC PARP1 degrader is a PARP1 degrader based on MDM2 E3 ligand. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an IC50 of 6.12 μM. | ||
| M29690 | SK-575-NEG | PARP |
| SK-575-NEG (compound 28), a methylation counterpart of SK-575, is synthesized by methylation of the amino group of piperidine-2,6-dione in SK-575 as an control compound. SK-575-NEG is strongly bound to PARP1, with an IC50 of 2.64 nM. SK-575-NEG was completely ineffective in inducing PARP1 degradation in MDA-MB-436 and Capan-1 cells at concentrations up to 1 μM. | ||
| M41360 | PARP-1/2-IN-2 | PARP |
| PARP-1/2-IN-2-IN-1 is a PARP1/2/CDK12 inhibitor (IC50: 34, 30 and 285 nM respectively). | ||
| M42940 | ARTD3/PARP3-IN-1 | Others |
| ARTD3/PARP3-IN-1 is an unselective inhibitor of diphtheria toxin-like ADP-ribosyltransferase 3 (ARTD3)/PARP3. | ||
| M45107 | PARP/EZH2-IN-1 | PARP |
| PARP/EZH2-IN-1 is a first-in-class dual PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA. | ||
| M54523 | NMS-03305293 | PARP |
| NMS-293 | ||
| NMS-03305293 is a PARP inhibitor with high selectivity for PARP1 isoforms and low DNA capture effect, which specifically kills BRCA mutated tumor cells. In addition, NMS-03305293 can penetrate the blood-brain barrier and can be used in studies related to CNS tumors and brain metastatic tumors. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
